HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma.

AbstractAIM:
This study aimed to analyze the expression, clinical significance of stanniocalcin 2 in cervical carcinoma patients who were treated with radiotherapy.
METHODS:
Stanniocalcin 2 expression was determined by real-time PCR in 10 pairs of cervical cancer and adjacent normal cervical tissues. Tumor samples from 92 patients diagnosed from 2004 to 2007 were studied. All samples were obtained prior to treatment start. All cases were clinically diagnosed and pathologically confirmed to be cervical carcinoma without distant metastasis, and have been treated with radical radiation therapy and followed-up for five years. The samples were immunohistochemically analyzed for stanniocalcin 2 expression and survival analyses were performed.
RESULTS:
The tumors of cervical cancer patients had significantly increased expression of stanniocalcin 2 at mRNA level compared with adjacent normal cervical tissues. High levels of stanniocalcin 2 expression was correlated with shorter overall survival, whereas low levels of stanniocalcin 2 expression was correlated with longer overall survival (P = 0.003) and progression free survival (P = 0.001) after radiotherapy. Moreover, high expression of stanniocalcin 2 was correlated with lymph node metastasis (P = 0.002).
CONCLUSION:
Stanniocalcin 2 could be a useful marker for the prognosis of cervical cancer patients receiving radiotherapy. Stanniocalcin 2 may contribute to tumor development and radioresistance in cervical cancer.
AuthorsXiao-Jian Shen, Ke Gu, Jian-Ping Shi, Jian-Qin Yao, Jin-Chang Wu
JournalInternational journal of clinical and experimental pathology (Int J Clin Exp Pathol) Vol. 7 Issue 12 Pg. 8770-6 ( 2014) ISSN: 1936-2625 [Electronic] United States
PMID25674244 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Glycoproteins
  • Intercellular Signaling Peptides and Proteins
  • STC2 protein, human
  • Cisplatin
Topics
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage)
  • Biomarkers, Tumor (analysis)
  • Brachytherapy (methods)
  • Carcinoma (mortality, pathology, radiotherapy)
  • Chemoradiotherapy
  • Cisplatin (administration & dosage)
  • Disease Progression
  • Disease-Free Survival
  • Female
  • Glycoproteins (biosynthesis)
  • Humans
  • Immunohistochemistry
  • Intercellular Signaling Peptides and Proteins (biosynthesis)
  • Kaplan-Meier Estimate
  • Lymphatic Metastasis (pathology)
  • Middle Aged
  • Prognosis
  • Proportional Hazards Models
  • Radiation Tolerance (physiology)
  • Radiotherapy, Conformal
  • Real-Time Polymerase Chain Reaction
  • Uterine Cervical Neoplasms (mortality, pathology, radiotherapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: